Immunotherapy of experimental autoimmune myasthenia gravis: Selective effects of CTLA4Ig and synergistic combination with an IL2-Diphtheria toxin fusion protein

Journal of Neuroimmunology

Volumn 87, Issue 1-2, 1998, Pages 136-146

  McIntosh, Kevin R ^a   Linsley, Peter S ^b   Bacha, Patricia A ^c   Drachman, Daniel B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c Seragen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENILEUKIN DIFTITOX; HYBRID PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; IMMUNOTHERAPY; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBODY FORMATION; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; AUTOANTIBODIES; DIPHTHERIA TOXIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTERLEUKIN-2; MYASTHENIA GRAVIS; RATS; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC; RECOMBINANT FUSION PROTEINS; REFERENCE VALUES;

EID: 0032126158     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00071-X     Document Type: Article

References (60)

1. Arima, T., Rehman, A., Hickey, W.F., Flye, M.W., 1996. Inhibition by CTLA4Ig of experimental allergic encephalomyelitis. J. Immunol. 156, 4916-4924.
2. Bacha, P., Williams, D.P., Waters, C., Williams, J.M., Murphy, J.R., Strom, T.B., 1988. Interleukin-2 targeted cytotoxicity: interleukin-2 receptor-mediated action of a diphtheria toxin-related interleukin-2 fusion protein. J. Exp. Med. 167, 612-622.
3. Beverly, B., Kang, S.-M., Lenardo, M.J., Schwartz, R.H., 1992. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int. Immunol. 4, 661-671.
4. Constant, S.L., Bottomly, K., 1997. Induction of Th1 and Th2 CD4+T cell responses: the alternative approaches. Annu. Rev. Immunol. 15, 297-322.
5. Cua, D.J., Hinton, D.R., Stohlman, S.A., 1995. Self-antigen-induced Th2 responses in experimental allergic encephalomyelitis (EAE)-resistant mice. Th2-mediated suppression of autoimmune disease. J. Immunol. 155, 4052-4059.
6. Drachman, D.B., 1981. Biology of myasthenia gravis. Annu. Rev. Neurosci. 4, 195-225.
7. Drachman, D.B., 1994. Myasthenia gravis. New Engl. J. Med. 330, 1797-1810.
8. Drachman, D.B., McIntosh, K.R., DeSilva, S., Kuncl, R.W., Kahn, C., 1988. Strategies for the treatment of myasthenia gravis. Ann. New York Acad. Sci. 540, 176-186.
9. Eldefrawi, M.E., Eldefrawi, A.T., 1973. Purification and molecular properties of the acetylcholine receptor from torpedo electroplax. Arch. Biochem. Biophys. 159, 363-373.
10. Engel, A.G., 1984. Myasthenia gravis and myasthenic syndromes. Ann. Neurol. 16 (5), 519-534.
11. Finck, B.K., Linsley, P.S., Wofsy, D., 1994. Treatment of murine lupus with CTLA4Ig. Science 265, 1225-1227.
12. Finkelman, F.D., Holmes, J., Katona, I.M., Urban, J.F., Beckmann, M.P., Paul, W.E., 1990. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 8, 303-333.
13. Gause, W.C., Chen, S.J., Greenwald, R.J., Halvorsen, M.J., Lu, P., Zhou, X., Morris, S.C., Lee, K.P., June, C.H., Finkelman, F.D., Urban, J.F., Abe, R., 1997. CD28 dependence of T cell differentiation to IL-4 production varies with the particular type 2 immune response. J. Immunol. 158, 4082-4087.
14. Gomez, C.M., Richman, D.P., 1985. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis. J. Immunol. 135 (1), 234-241.
15. Gracie, J.A., Bradley, J.A., 1996. Interleukin-12 induces interferon-gamma-dependent switching of IgG alloantibody subclass. Eur. J. Immunol. 26, 1217-1221.
16. Hohlfeld, R., Toyka, K.V., Michels, M., Heininger, K., Conti-Tronconi, B., Tzartos, S.J., 1987. Acetylcholine receptor-specific human T-lymphocyte lines. Ann. New York Acad. Sci. 505, 27-38.
17. Judge, T.A., Tang, A., Spain, L.M., Gratiot-Deans, J., Sayegh, M.H., Turka, L.A., 1996. The in vivo mechanism of action of CTLA4Ig. J. Immunol. 156, 2294-2299.
18. Kiyokawa, T., Williams, D.P., Snider, C.E., Strom, T.B., Murphy, J.R., 1991. Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells. Protein Eng. 4, 463-468.
19. Kuchroo, V.K., Das, M.P., Brown, J.A., Ranger, A.M., Zamvil, S.S., Sobel, R.A., Weiner, H.L., Nabavi, N., Glimcher, L.H., 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80, 707-718.
20. Lennon, V.A., Lindstrom, J.M., Seybold, M.E., 1975. Experimental autoimmune myasthenia gravis: a model of myasthenia gravis in rats and guinea pigs. J. Exp. Med. 141, 1365-1375.
21. Lennon, V.A., Lindstrom, J.M., Seybold, M.E., 1976. Experimental autoimmune myasthenia gravis: cellular and humoral aspects. Ann. New York Acad. Sci. 274, 283-299.
22. Lenschow, D.J., Zeng, Y., Thistlethwaite, J.R., Montag, A., Brady, W., Gibson, M.G., Linsley, P.S., Bluestone, J.A., 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 257, 789-792.
23. Lenschow, D.J., Walunas, T.L., Bluestone, J.A., 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14, 233-258.
24. Lin, H., Bolling, S.F., Linsley, P.S., Wei, R.-Q., Gordon, D., Thompson, C.B., Turka, L.A., 1993. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J. Exp. Med. 178, 1801-1806.
25. Lindstrom, J., 1985. Immunobiology of myasthenia gravis, experimental autoimmune myasthenia gravis, and Lambert-Eaton syndrome. Annu. Rev. Immunol. 3, 109-131.
26. Link, H., Olsson, O., Sun, J., Wang, W., Andersson, G., Ekre, H., Brenner, T., Abramsky, O., Olsson, T., 1991. Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J. Clin. Invest. 87, 2191-2196.
27. Linsley, P.S., Ledbetter, J.A., 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11, 191-212.
28. Linsley, P.S., Brady, W., Urnes, M., Grosmaire, L.S., Damle, N.K., Ledbetter, J.A., 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174, 561-569.
29. Linsley, P.S., Wallace, P.M., Johnson, J., Givson, M.G., Greene, J.L., Ledbetter, J.A., Singh, C., Tepper, M.A., 1992. Immunosuppression in vivo by a soluble form of the CTLA4 T cell activation molecule. Science 257, 792-795.
30. Lu, P., Zhou, X., Chen, S.J., Moorman, M., Morris, S.C., Finkelman, F.D., Linsley, P., Urban, J.F., Gause, W.C., 1994. CTLA4-Ig ligands are required to induce an in vivo interleukin 4 response to a gastro-intestinal nematode parasite. J. Exp. Med. 180, 693-698.
31. Maccioni, M., Rivero, V., Riera, C.M., 1996. Autoantibodies against rat prostate antigens. Association of specific IgG2b and IgG2c with the DTH response. J. Autoimmun. 9, 485-491.
32. McArthur, J.G., Raulet, D.H., 1993. CD28-induced costimulation of T helper type 2 cells mediated by induction of responsiveness to interleukin 4. J. Exp. Med. 178, 1645-1653.
33. McIntosh, K.R., Drachman, D.B., 1992. Tolerance to acetylcholine receptor induced by AChR-coupled syngeneic cells. J. Neuroimmunol. 38, 75-84.
34. McIntosh, K.R., Drachman, D.B., Kuncl, R.W., 1989. Antigen-specific suppressor macrophages induced by culture with cyclosporin A plus acetylcholine receptor. J. Neuroimmunol. 25 (1), 75-89.
35. McIntosh, K.R., Linsley, P.S., Drachman, D.B., 1995. Immunosuppression and induction of anergy in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis. Cell. Immunol. 166, 103-112.
36. Melms, A., Chrestel, S., Schalke, B.C., Wekerle, H., Mauon, A., Ballivet, M., Barkas, T., 1989. Autoimmune T lymphocytes in myasthenia gravis: determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene. J. Clin. Invest. 83, 785-790.
37. Miller, S.D., Vanderlugt, C.L., Lenschow, D.J., Pope, J.G., Karandikar, N.J., dal Canto, M.C., Bluestone, J.A., 1995. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 3, 739-745.
38. Mosmann, T.R., Coffman, R.L., 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145-173.
39. Newsom-Davis, J., Harcourt, G., Sommer, N., Beeson, D., Willcox, N., Rothbard, J.-B., 1989. T cell reactivity in myasthenia gravis. J. Autoimmun. 2, 101-108, (suppl).
40. Nishikawa, K., Linsley, P.S., Collins, A.B., Stamenkovic, I., McCluskey, R.T., Andres, G., 1994. Effect of CTLA4Ig on rat autoimmune anti-GBM glomerulonephritis. Eur. J. Immunol. 24, 1249-1254.
41. Patrick, J., Lindstrom, J., 1973. Autoimmune response to acetylcholine receptor. Science 180, 871-872.
42. Penn, A.S., Richman, D.P., Ruff, R.L., Lennon, V.A., 1993. Myasthenia gravis and related disorders: experimental and clinical aspects. Ann. New York Acad. Sci. 681, 1-622.
43. Pestronk, A., Drachman, D.B., Teoh, R., Adams, R.N., 1983. Combined short-term immunotherapy cures experimental autoimmune myasthenia gravis. Ann. Neurol. 14 (2), 235-241.
44. + cell lines from myasthenia gravis patients. J. Immunol. 144, 1711-1720.
45. Protti, M.P., Manfredi, A.A., Horton, R.M., Bellone, M., Conti-Tronconi, B.M., 1993. Myasthenia gravis: recognition of a human autoantigen at the molecular level. Immunol. Today 14, 363-368.
46. Rittenberg, M.B., Pratt, K.L., 1969. Antitrinitrophenyl (TNP) plaque assay. Primary response of Balb/c mice to soluble and particulate immunogen. Proc. Soc. Exp. Biol. Med. 132 (2), 575-581.
47. + T cells and defective antibody production in vivo. J. Exp. Med. 179 (3), 809-917.
48. Sayegh, M.H., Akalin, E., Hancock, W.W., Russell, M.E., Carpenter, C.B., Linsley, P.S., Turka, L.A., 1995. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J. Exp. Med. 181, 1869-1874.
49. Schwartz, R.H., 1990. A cell culture model for T lymphocyte clonal anergy. Science 248, 1349-1356.
50. Schwartz, R.H., 1992. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71, 1065-1068.
51. Subtil, A., Hemar, A., Dautry-Varsat, A., 1994. Rapid endocytosis of interleukin 2 receptors when clathrin-coated pit endocytosis is inhibited. J. Cell Sci. 107, 3461-3468.
52. Tan, P., Anasetti, C., Hansen, J.A., Melrose, J., Brunvand, M., Bradshaw, J., Ledbetter, J.A., Linsley, P.S., 1993. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J. Exp. Med. 177, 165-173.
53. Turka, L.A., Linsley, P.S., Lin, H., Brady, W., Leiden, J.M., Wei, R.-Q., Gibson, M.L., Zheng, X.-G., Myrdal, S., Gordon, D., Bailey, T., Bolling, S.F., Thompson, C.B., 1992. T cell activation by the CD28-ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. U.S.A. 89 (2), 11102-11105.
54. Wallace, P.M., Rodgers, J.N., Leytze, G.M., Johnson, J.S., Linsley, P.S., 1995. Induction of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment. J. Immunol. 154 (11), 5885-5895.
55. Wasowska, B., Wieder, K.J., Hancock, W.W., Zheng, X.X., Berse, B., Binder, J., Strom, T.B., Kupiec-Weglinski, J.W., 1996. Cytokine and alloantibody networks in long term cardiac allografts in rat recipients treated with rapamycin. J. Immunol. 156, 395-404.
56. Wauben, M.H.M., Hoedemaekers, A.C.W.E., Graus, Y.M.F., Wagenaar, J.P.A., van Eden, W., de Baets, M.H., 1996. Inhibition of experimental autoimmune myasthenia gravis by major histocompatibility complex class II competitor peptides results not only in a suppressed but also in an altered immune response. Eur. J. Immunol. 26, 2866-2875.
57. 486-IL2): fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J. Biol. Chem. 265 (20), 11885-11889.
58. Yang, B., McIntosh, K.R., Drachman, D.B., 1998. How subtle differences in MHC class II affect the severity of experimental myasthenia gravis. Clin. Immunol. Immunopathol. 86, 45-58.
59. Yeh, T.-M., Krolick, K.A., 1989. Clonotypic analysis of anti-acetylcholine receptor antibodies produced against native and denatured antigen. J. Neuroimmunol. 24 (1-2), 133-142.
60. Yi, Q., Pirskanen, R., Lefvert, A.K., 1993. Human muscle acetylcholine receptor reactive T and B lymphocytes in the peripheral blood of patients with myasthenia gravis. J. Neuroimmunol. 42, 215-222.